Inhibrx Biosciences (NASDAQ:INBX) Price Target Cut to $220.00 by Analysts at HC Wainwright

Inhibrx Biosciences (NASDAQ:INBX – Get Free Report) had its target price reduced by investment analysts at HC Wainwright from $245.00 to $220.00 in a report released on Monday, Benzinga reports. The brokerage currently has a “buy” rating on the stock. HC Wainwright‘s price objective would suggest a potential upside of 164.11% from the company’s current price.

INBX has been the topic of several other reports. Citigroup reiterated a “market perform” rating on shares of Inhibrx Biosciences in a research note on Friday, September 18th. Weiss Ratings restated a “sell (d-)” rating on shares of Inhibrx Biosciences in a research note on Friday, September 11th. Finally, Wall Street Zen cut Inhibrx Biosciences from a “hold” rating to a “strong sell” rating in a report on Monday, August 17th. One equities research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $185.00.

Get Our Latest Stock Report on INBX

Inhibrx Biosciences Price Performance

NASDAQ INBX opened at $83.30 on Monday. Inhibrx Biosciences has a 12-month low of $57.30 and a 12-month high of $155.29. The company has a market capitalization of $1.23 billion, a PE ratio of -9.19 and a beta of 4.03. The firm’s 50 day moving average is $95.27 and its 200-day moving average is $92.14.

Inhibrx Biosciences (NASDAQ:INBX – Get Free Report) last announced its quarterly earnings data on Friday, November 13th. The company reported ($2.46) EPS for the quarter, missing analysts’ consensus estimates of ($2.45) by ($0.01). The firm had revenue of $2.00 million for the quarter, compared to analyst estimates of $1.90 million. As a group, sell-side analysts expect that Inhibrx Biosciences will post -9.91 EPS for the current year.

Insider Transactions at Inhibrx Biosciences

In related news, CEO Mark Lappe acquired 10,040 shares of the business’s stock in a transaction dated Wednesday, October 14th. The stock was bought at an average price of $84.56 per share, with a total value of $848,982.40. Following the acquisition, the chief executive officer owned 745,588 shares in the company, valued at $63,046,921.28. This represents a 1.36% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Jon Kayyem acquired 5,000 shares of the business’s stock in a transaction dated Wednesday, September 23rd. The stock was bought at an average cost of $100.00 per share, with a total value of $500,000.00. Following the acquisition, the director owned 434,360 shares in the company, valued at $43,436,000. The trade was a 1.16% increase in their position. The disclosure for this purchase is available in the SEC filing. In the last 90 days, insiders have purchased 62,540 shares of company stock worth $6,347,507 and have sold 1,500 shares worth $168,590. Company insiders own 18.26% of the company’s stock.

Institutional Trading of Inhibrx Biosciences

A number of large investors have recently added to or reduced their stakes in INBX. Opaleye Management Inc. acquired a new position in shares of Inhibrx Biosciences during the 2nd quarter worth about $1,923,000. Nicholas Investment Partners LP bought a new stake in shares of Inhibrx Biosciences in the 2nd quarter valued at about $2,032,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its stake in Inhibrx Biosciences by 29,850.7% in the 2nd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 20,067 shares of the company’s stock valued at $1,901,000 after purchasing an additional 20,000 shares during the last quarter. Western Standard LLC acquired a new stake in Inhibrx Biosciences in the 2nd quarter valued at about $4,453,000. Finally, Bank of New York Mellon Corp acquired a new stake in Inhibrx Biosciences in the 2nd quarter valued at about $2,482,000. Institutional investors and hedge funds own 82.46% of the company’s stock.

Inhibrx Biosciences Company Profile

(Get Free Report)

Inhibrx Biosciences, Inc. is a U.S.-based biopharmaceutical company focused on developing biologic medicines for cancer and other serious diseases. Its research uses protein engineering to create investigational therapies designed to engage specific targets in the body. The company’s oncology pipeline has included INBRX-109, an antibody designed to activate the DR5 receptor and studied for chondrosarcoma, and INBRX-106, an investigational OX40-targeting antibody. These candidates are experimental and are not approved medicines.

Featured Stories

Analyst Recommendations for Inhibrx Biosciences (NASDAQ:INBX)

Receive News & Ratings for Inhibrx Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inhibrx Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.